Skip Navigation

JNCI Journal of the National Cancer Institute 2009 101(15):1033; doi:10.1093/jnci/djp247
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

The Costs of Cancer Therapies

Citing the addition of cetuximab to standard therapy for non-small cell lung cancer, Fojo and Grady (p. 1044) comment on the tendency of oncologists to adopt therapies that offer only marginal improvement in overall or progression-free survival often with risks of serious side effects. Despite their limited benefits, the therapies usually add tens of thousands of dollars to the cost of treating a patient. The authors suggest that one should not automatically assume that approval of expensive new treatments with limited effects on survival will lead to the identification of a subset of patients who will derive substantial benefit or lay the groundwork for . . . [Full Text of this Article]

Phase III Trial of Thalidomide in Small Cell Lung Cancer

Hormone Receptor Status and Risk of Second Primary Breast Tumor

Hepatitis B Virus Mutations and the Risk of HCC

Cost-Effectiveness of HPV Vaccination in the Netherlands


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?